MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Consensus Ratings for Intra-Cellular Therapies (NASDAQ:ITCI) (?)
Ratings Breakdown: 6 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.14)
Consensus Price Target: $76.86 (105.89% upside)

Analysts' Ratings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Show:
DateFirmActionRatingPrice TargetActions
4/30/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016SunTrustReiterated RatingTop Pick$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$62.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015RBC CapitalBoost Price TargetOutperform$62.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015GuggenheimBoost Price TargetBuy$95.00 -> $104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015Ladenburg ThalmannReiterated RatingBuy$54.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/30/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha